Trega Biosciences, Inc.

Gensia Pharmaceuticals, Inc.

Eli Lilly and Company

Lion Bioscience Ag

Houghten Pharmaceuticals, Inc.

University of Texas System

Gensia, Inc.

Baker Cumins Dermatologicals, Inc.

Ronald R Tuttle

Beverly E Girten

Clinton E Browne

Richard Allen Houghten

Mark J Suto

Costas C Loullis

Klaus K Schmiegel

David B Anderson

Edward L Veenhuizen

Paul Omholt

Harry E Gruber

Yazhong Pei

Bheemarao G Ugarkar

Paul J Marangos

Hengyuan Lang

Timothy Gahman

Ernest K Metzner

Amaresh Basu

Kevin Ross Holme

Sandra R Slivka

Edmund J Miller

Shinichiro Hayashi

Patricia A Weber

Jack Mills

Karen J Watson-Straughan

Jack W Reich

J R Thornton

Douglas L Hitchin

Kevin C Dines

Patrick Fagan

Ali Andalibi

Anna K Kurdowska

Allen Barry Cohen, Deceased

Methods for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X &mdash;X -(D)Phe-Arg-(D)Trp-X . A particularly useful compound is HP-228, which has the formula Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH . The invention also provides methods for selecting melanocortin receptor-3 ligands by determining whether a compound modulates the activity of MC-3 as an agonist or antagonist. These methods can be used to screen compound libraries for ligands to treat MC-3-associated conditions. Such conditions include sexual dysfunction, including erectile dysfunction and sexual arousal disorder.

Melanocortin receptor-3 ligands to treat sexual dysfunction

HP-3228 and related peptides to treat sexual dysfunction

The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.

Cytokine restraining agents

Methods of inhibiting CXC intercrine molecules

The present invention provides methods for reducing the severity of GI damage in an individual by administering a cytokine regulatory agent to an individual that is susceptible to developing such damage.

Method for reducing the severity of gastro-intestinal damage

The present invention relates to the use of cytokine restraining agents to treat inflammatory bowel disease.

Use of cytokine restraining agents to treat inflammatory bowel disease

The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.

Cytokine restraining agents and methods of use in pathologies and

The present invention relates to the use of a cytokine regulatory agent to reduce the severity of rheumatoid arthritis.

Use of a cytokine regulatory agent to treat rheumatoid arthritis

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.

Cytokine regulatory agents and methods of use in pathologies and

AICA riboside and prodrugs of AICA riboside are provided which lower blood glucose for the treatment of various pathologic conditions, including hypoglycemia, insulin deficiency, insulin resistance diabetes and Syndrome X. Prodrugs of AICA riboside provide AICA riboside in an orally bioavailable form. The use of adenosine kinase inhibition and ZMP enhancement for lowering blood glucose are also described.

Method and compounds for aica riboside delivery and for lowering blood

.beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.

Growth promotion

The present invention provides a method of reducing a wasting condition, which can occur due to a pathology or to a particular physiologic or metabolic state in a subject, by administering to the subject a substituted 1,3-benzodioxole.

Use of a substituted 1,3-benzodioxole to reduce a wasting condition

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

Diagnosis, evaluation and treatment of coronary artery disease by

Growing community of inventors

Escondido, CA, United States of America

Ronald R Tuttle